Navigation Links
Study: Communicating health risk is a risky task for FDA
Date:1/19/2012

One-third of those articles focused on antidepressants.

The researchers sorted FDA risk communications into four categories: warnings about serious adverse events, recommendations against use in specific patient populations, preventing harmful drug-drug interactions, and calls for increased laboratory or clinical monitoring.

The most effective notices were those warning the public about potential serious adverse events, but even these varied in their impact. For example, several studies found that patients shifted away from the diabetes drug rosiglitazone after an FDA alert noted an increased risk of cardiovascular events with this drug. This led to decreased use of rosiglitazone and increased use of other, less risky anti-diabetes drugs.

A similar 2010 FDA warning for asthma patients, however, had little effect. It stressed that one class of asthma medications known as long-acting beta agonists should not be used without an asthma controller medication, such as inhaled corticosteroids. Rates of controller medication use with long-acting beta agonists were low before the FDA warning and did not significantly increase after the advisory was issued.

Recommendations that specific groups of patients avoid certain medications sometimes decreased use, but also produced unintended consequences. The most notable was a series of advisories about the use of antidepressants among children and adolescents. The widely publicized alerts significantly decreased use of these medications by adults as well as children, and one study suggested an unexpected increase in suicides among children and adolescents due to increases in untreated depression.

FDA warnings about harmful drug-drug interactions had some impact, although reductions in co-prescribing that occurred often required repeated risk advisories and took months to years. For example, initial messages to reduce the use of cisapride with contraindicated products were first sent
'/>"/>

Contact: John Easton
John.Easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study: Crop diversity myths persist in media
2. Study: Residential washers may not kill hospital-acquired bacteria
3. UF-led study: Invasive amphibians, reptiles in Florida outnumber world
4. Study: New process that can save at-risk cancer patients is effective and significantly less costly
5. Study: Severe low temperatures devastate coral reefs in Florida Keys
6. Study: Climate change to increase Yellowstone wildfires dramatically
7. Study: People at risk for panic buffered from stressor by high levels of physical activity
8. Study: Preventive use of one form of natural vitamin E may reduce stroke damage
9. Study: Wild Cuban crocodiles hybridize with American crocs
10. Smithsonian study: Stranding records are faithful reflection of live whale and dolphin populations
11. Study: Biodegradable products may be bad for the environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/23/2015)... 23, 2015 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its second quarter ended June 30, 2015.  ... was $4.5 million, a decrease of 33% compared to $6.8 ... the second quarter of 2015 was $0.3 million, or $0.01 ... per diluted share, in the same period a year ago.  ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... children were born in public clinics in Denmark, projecting a net ... 50 years respectively. The authors of the study calculated that reductions ... to cost savings of 67 - 111 million for the Danish ... 50 years of age, the government would have lost 74 - ...
... 6, 2011 A first-of-its-kind study of a patient with lung ... the Virginia G. Piper Cancer Center at Scottsdale Healthcare at the ... Researchers for the first time sequenced the entire DNA and RNA ... Glen Weiss, the first author of the study, which will be ...
... bird, the statuesque whooping crane ( Grus americana ), is ... Smithsonian,s National Zoological Park. An 11-year-old male whooping crane named ... now on exhibit in the nation,s capital. Whooping cranes are ... States. There are only eight other zoos in the U.S. ...
Cached Biology News:The long-term fiscal impact of funding cuts for IVF in Denmark 2First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conference 2National Zoo Welcomes Whooping Crane 2
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... is making,progress in the development of sustainable biofuels. The recent first crop of,genetically modified poplars of the Flemish Institute for Biotechnology (VIB),will be modified into bioethanol in a Flemish-Dutch pilot ... , ... ... ...
... He is joined by scientists scattered from Ann Arbor to Osaka on the annual Thomson Reuters list of the world,s 12 hottest researchers. , ... , ... ... ...
... ... Kimberly Thompson wins $5,000 in CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough ... the economics category of the 2009 CUNY Nobel Science Challenge—as well as $5,000 as an ...
Cached Biology Technology:Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 2Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 3Thomson Reuters Names the World's 'Hottest' Researchers 2Thomson Reuters Names the World's 'Hottest' Researchers 3Thomson Reuters Names the World's 'Hottest' Researchers 4Thomson Reuters Names the World's 'Hottest' Researchers 5BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
... one of the several main MAP kinase ... a sensitive reporter for studying gene regulation ... in sensitivity in comparison to the standard ... the oxidative carboxylation of luciferin, a reaction ...
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
Biology Products: